Seizing Opportunities in Japan, the Second Largest Innovation-Driven Pharmaceutical Market
Webinar
Date
October 23, 2018
7:00AM - 7:50AM
Calendar

Summary

Japan is—and will remain—the second largest market for branded pharmaceuticals and innovation. Continued investment in development and commercialization of pharmaceuticals in Japan is creating many opportunities and growing the potential for multinational biopharma companies. This is driven in part by ongoing regulatory and government initiatives that reward innovation, shifts in population demographics, and increased disease awareness and identifiable patient populations, amongst other factors. Join IQVIA Japan as we discuss how to seize these opportunities and the strong potential outlook for the market in the coming years

Key Takeaways

  1. To obtain the information about the market in Japan
  2. How to seize the opportunity in this strong potential market
  3. The potential of the market in Japan in coming year
Speaker

Alan Thomas

Director, Thought Leadership IQVIA Solutions Japan K.K.

Alan Thomas joined IQVIA (then IMS Japan) in 1999, supporting multinational pharma companies in the Japan market. In 2002, he was appointed Manager Japan Global Accounts, supporting Japanese pharma companies with sales, marketing and consulting services for Japan, Europe, USA, China and AsiaPacific. In 2004, he was appointed Global Key Account Manager and in 2006 he was appointed Global Key Account Director, a position he held until January 2011 when he was appointed Director Global Pharma Segmentation and Account Management, a role in which Alan worked with IMS teams globally to deliver expanded business intelligence and decision support to pharma companies - both Japanese and foreign multinationals. In 2012, Alan took on an expanded role supporting the wider healthcare stakeholder community. In this role, Alan supported the IQVIA thought leadership and market insights initiatives globally, and strengthened Japan’s thought leadership position. In 2016, Alan was appointed Director Thought Leadership and in this role he continues to engage with the wider healthcare stakeholder community, supporting the integrated IQVIA thought-leadership and market insights teams, and leading Japan’s thought leadership position.